In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh